Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > JDRF-funded smart insulin research shows promise
JDRF-funded researchers in China led by Professor Zhen Gu have developed a new form of glucose-responsive insulin, also known as smart insulin, which is given orally. In a research paper published today in Nature Nanotechnology, the researchers explain how the smart insulin (which is a mixture of insulin and another molecule) passes through the stomach and lies stable in a reservoir in the liver.
Once the molecule detects rising blood glucose levels, it releases just enough insulin from the reservoir to lower blood glucose to a safe level. More testing needs to be done before this can be given to people living with type 1 diabetes, but promising results from animal studies show good progress towards clinical trials.
The researchers hope to develop the design of the smart insulin so that it can be given to people with type 1 diabetes. He hopes that in the future this type of insulin will be able to reduce the need for multiple daily insulin injections and limit the highs and lows in blood glucose that people living with type 1 diabetes experience.
The smart insulin enters the stomach in ‘worm-like’ molecules, which are absorbed faster than currently available insulins. The insulin worms move from the stomach into the liver where they form an inactive reservoir. The smart insulin contains a molecule that detects high levels of glucose and triggers the release of insulin in response. Because the insulin is already waiting in the liver, it can get to the glucose in the blood and remove it faster than injections of currently available insulin.
The researchers gave the smart insulin to mice with type 1 diabetes. They found the insulin was quickly released from its reservoir at a dose that matched the excess glucose in the mice’s blood. Any leftover insulin released was removed quickly by the mice’s bodies without causing hypoglycaemia. The study also had promising safety results, with no short- or long-term side effects of the smart insulin.
When the researchers tested the smart insulin in pigs with type 1 diabetes, which are biologically similar to humans, the insulin was able to lower the pigs’ blood glucose for 24 hours without causing any hypos. These results make the researchers optimistic that their insulin design would be safe and effective for people with type 1 diabetes.
Through the Type 1 Diabetes Grand Challenge, our partnership with Diabetes UK and the Steve Morgan Foundation, we are funding Dr Zhen Gu to fine-tune the insulin to make it more effective. The team will then test their insulin to make sure it is released properly from the reservoir when blood glucose levels rise to keep them in a safe range in animals with diabetes. This year-long research project will bring smart insulin closer to clinical trials in people with type 1 diabetes.
Prof Zhen Gu said: “The clinical translation of this long-acting smart insulin will significantly enhance health and quality of life of people with type 1 diabetes.”
Donate to help fund more research breakthroughs.
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
A study we helped conduct, which has just been published, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the United Kingdom and Ireland. This will help guide future research to focus on what matters most to people living with the condition.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
